AI Maverick Intel Inc. (OTCID: AIMV) has entered into a definitive share purchase agreement to acquire Heal Access Canada Inc., an artificial intelligence healthcare technology company, from its controlling stockholder, HEAL Group Holdings Inc. The deal, announced by TechMediaWire, marks a significant step for AIMV as it seeks to establish a foothold in the rapidly growing AI-powered healthcare sector. However, the transaction comes with substantial conditions and implications that investors should carefully consider.
Heal Access operates an AI-powered healthcare intelligence platform that integrates patient information and supports clinical workflows. The platform is already operational in five countries and serves more than 118,000 patients, according to the press release. For AIMV, acquiring Heal Access would provide an immediate commercial-stage asset and a scalable technology foundation. The company has stated that it intends to grow through Heal Access and through further acquisitions of AI and technology-enabled healthcare businesses, including opportunities available under its right of first refusal agreement with HEAL Group. This strategy positions AIMV as a potential consolidator in the AI healthcare space.
The consideration for the acquisition includes $5 million through a secured, two-year promissory note bearing 10% annual interest, plus 20 million exchangeable shares convertible into AIMV common stock. Additionally, AIMV will assume approximately $6.4 million in existing obligations owed by Heal Access and its subsidiaries to HEAL Group and affiliates. Upon conversion of all exchangeable shares, HEAL Group would hold approximately 80.1% of AIMV common stock before accounting for any shares issued in the financing. This means that existing AIMV shareholders could face massive dilution, and control of the company would shift decisively to HEAL Group.
The acquisition remains subject to several closing conditions, including at least $6 million in financing and independent special committee ratification. AIMV expects to use commercially reasonable efforts to complete the required financing by Dec. 31, 2026, with either party permitted to terminate the agreement if the transaction has not closed by Feb. 28, 2027. These conditions introduce significant execution risk. Failure to secure financing could derail the deal, leaving AIMV without the anticipated benefits of the acquisition. Investors can find more details in the full press release available at https://ibn.fm/1XVOv.
AIMV also clarified that its Sept. 21 announcement incorrectly described the acquisition agreement as definitive, noting that the binding agreement was signed Oct. 12, 2026. This correction raises questions about the company's prior communications and underscores the importance of accurate disclosure. The latest news and updates relating to AIMV are available in the company's newsroom at http://ibn.fm/AIMV, which investors may wish to monitor for further developments.
The announcement was distributed through InvestorWire, a wire service that provides editorial syndication to 5,000+ outlets, ensuring broad reach. For those interested in the dissemination process, details on press release enhancement are also available. As with all investment opportunities, readers should review the full terms of use and disclaimers on the TechMediaWire website at https://www.TechMediaWire.com/Disclaimer.
